{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:50Z","timestamp":1761896390686,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Servier International"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00125-016-4082-5","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T23:38:27Z","timestamp":1472773107000},"page":"2603-2612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes"],"prefix":"10.1007","volume":"59","author":[{"given":"Joep","family":"van der Leeuw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank L. J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Harrap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"4082_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","volume":"103","author":"L Guariguata","year":"2014","unstructured":"Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137\u2013149","journal-title":"Diabetes Res Clin Pract"},{"key":"4082_CR2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405\u2013412","journal-title":"BMJ"},{"key":"4082_CR3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421\u2013431","journal-title":"Ann Intern Med"},{"key":"4082_CR4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-011-2404-1","volume":"55","author":"S Zoungas","year":"2012","unstructured":"Zoungas S, Chalmers J, Ninomiya T et al (2012) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55:636\u2013643","journal-title":"Diabetologia"},{"key":"4082_CR5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837\u2013853","journal-title":"Lancet"},{"key":"4082_CR6","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169","journal-title":"BMJ"},{"key":"4082_CR7","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288\u20132298","journal-title":"Diabetologia"},{"key":"4082_CR8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SRK, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765\u20131772","journal-title":"Lancet"},{"key":"4082_CR9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589","journal-title":"N Engl J Med"},{"key":"4082_CR10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","volume":"151","author":"TN Kelly","year":"2009","unstructured":"Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394\u2013403","journal-title":"Ann Intern Med"},{"key":"4082_CR11","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410\u20131418","journal-title":"N Engl J Med"},{"key":"4082_CR12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559","journal-title":"N Engl J Med"},{"key":"4082_CR13","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035\u20133087","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"4082_CR14","first-page":"S1","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association (2015) Standards of medical care in diabetes\u20142015. Diabetes Care 38(Suppl 1):S1\u2013S93","journal-title":"Diabetes Care"},{"key":"4082_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/eurheartj\/ehu004","volume":"35","author":"J Leeuw van der","year":"2014","unstructured":"van der Leeuw J, Ridker PM, van der Graaf Y, Visseren FLJ (2014) Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J 35:837\u2013843","journal-title":"Eur Heart J"},{"key":"4082_CR16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jamainternmed.2014.2894","volume":"174","author":"S Vijan","year":"2014","unstructured":"Vijan S, Sussman JB, Yudkin JS, Hayward RA (2014) Effect of patients\u2019 risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 174:1227\u20131234","journal-title":"JAMA Intern Med"},{"key":"4082_CR17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2015.7517","volume":"314","author":"A Benetos","year":"2015","unstructured":"Benetos A, Rossignol P, Cherubini A et al (2015) Polypharmacy in the aging patient. JAMA 314:170\u2013180","journal-title":"JAMA"},{"key":"4082_CR18","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","volume":"19","author":"Advance Management Committee","year":"2001","unstructured":"Advance Management Committee (2001) Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release. J Hypertens Suppl 19:S21\u2013S28","journal-title":"J Hypertens Suppl"},{"key":"4082_CR19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829\u2013840","journal-title":"Lancet"},{"key":"4082_CR20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jclinepi.2006.01.014","volume":"59","author":"ART Donders","year":"2006","unstructured":"Donders ART, van der Heijden GJMG, Stijnen T, Moons KGM (2006) Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59:1087\u20131091","journal-title":"J Clin Epidemiol"},{"key":"4082_CR21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"4082_CR22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"4082_CR23","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2337\/dc11-0755","volume":"34","author":"M Woodward","year":"2011","unstructured":"Woodward M, Patel A, Zoungas S et al (2011) Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care 34:2491\u20132495","journal-title":"Diabetes Care"},{"key":"4082_CR24","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"EW Steyerberg","year":"2009","unstructured":"Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating. Springer, New York"},{"key":"4082_CR25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell","year":"1996","unstructured":"Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361\u2013387","journal-title":"Stat Med"},{"key":"4082_CR26","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073\u20132081","journal-title":"Lancet"},{"key":"4082_CR27","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"DG Altman","year":"1999","unstructured":"Altman DG, Andersen PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492\u20131495","journal-title":"BMJ"},{"key":"4082_CR28","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/sim.5681","volume":"32","author":"TA Gerds","year":"2012","unstructured":"Gerds TA, Kattan MW, Schumacher M, Yu C (2012) Estimating a time-dependent concordance index for survival prediction models with covariate dependent censoring. Stat Med 32:2173\u20132184","journal-title":"Stat Med"},{"key":"4082_CR29","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560\u20132572","journal-title":"N Engl J Med"},{"key":"4082_CR30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 58:429\u2013442","journal-title":"Diabetologia"},{"key":"4082_CR31","doi-asserted-by":"crossref","first-page":"b5444","DOI":"10.1136\/bmj.b5444","volume":"340","author":"ME Miller","year":"2010","unstructured":"Miller ME, Bonds DE, Gerstein HC et al (2010) The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340:b5444","journal-title":"BMJ"},{"key":"4082_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-6-18","volume":"6","author":"RA Hayward","year":"2006","unstructured":"Hayward RA, Kent DM, Vijan S, Hofer TP (2006) Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 6:18","journal-title":"BMC Med Res Methodol"},{"key":"4082_CR33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1745-6215-11-85","volume":"11","author":"DM Kent","year":"2010","unstructured":"Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA (2010) Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 11:85","journal-title":"Trials"},{"key":"4082_CR34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2337\/dc09-1471","volume":"33","author":"J Calles-Escand\u00f3n","year":"2010","unstructured":"Calles-Escand\u00f3n J, Lovato LC, Simons-Morton DG et al (2010) Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33:721\u2013727","journal-title":"Diabetes Care"},{"key":"4082_CR35","doi-asserted-by":"crossref","first-page":"f324","DOI":"10.1136\/bmj.f324","volume":"346","author":"D Nitsch","year":"2013","unstructured":"Nitsch D, Grams M, Sang Y et al (2013) Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 346:f324","journal-title":"BMJ"},{"key":"4082_CR36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.diabres.2010.05.012","volume":"89","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Chalmers J, Kengne AP et al (2010) The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract 89:126\u2013133","journal-title":"Diabetes Res Clin Pract"},{"key":"4082_CR37","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","volume":"28","author":"ADA Workgroup on Hypoglycemia","year":"2005","unstructured":"ADA Workgroup on Hypoglycemia (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245\u20131249","journal-title":"Diabetes Care"},{"key":"4082_CR38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamainternmed.2013.2512","volume":"173","author":"ER Weitzman","year":"2013","unstructured":"Weitzman ER, Kelemen S, Quinn M, Eggleston EM, Mandl KD (2013) Participatory surveillance of hypoglycemia and harms in an online social network. JAMA Intern Med 173:345\u2013351","journal-title":"JAMA Intern Med"},{"key":"4082_CR39","volume":"6","author":"M Sharma","year":"2016","unstructured":"Sharma M, Nazareth I, Petersen I (2016) Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open 6, e010210","journal-title":"BMJ Open"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-016-4082-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:49:31Z","timestamp":1498326571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-016-4082-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["4082"],"URL":"https:\/\/doi.org\/10.1007\/s00125-016-4082-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}